Position in BHVN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$17,849,229
+$6,573,809 QoQ
Shares Held
1,199,545
-10.0% QoQ
Ownership
0.794%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#27
of 294 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BHVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Research Global Investors holds $14,161,458,348 across 17 Biotechnology names. BHVN ranks #17 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,490,637 | $9,681,584,117 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,750,699 | $2,935,252,919 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
3,504,387 | $200,521,024 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
5,344,701 | $199,197,006 | |
| 5 | TECH |
BIO-TECHNE Corp
|
2,621,890 | $185,236,528 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,532,303 | $170,131,602 | |
| 7 | KYMR |
Kymera Therapeutics, Inc.
|
1,388,881 | $159,262,984 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,686,625 | $143,683,583 |
All Filings in BHVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $17,849,229 | 1,199,545 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $11,275,420 | 1,332,792 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $15,047,221 | 1,332,792 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $15,183,065 | 1,011,530 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $6,831,963 | 484,193 | Shares | Defined | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||